Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121290 · ClinicalTrials.gov registry record · Phase 1
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00121290: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00121290 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00121290, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of SJG-136 in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG SJG-136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2005-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121290
The ClinicalTrials.gov registry entry for NCT00121290 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00121290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00121290 about?
NCT00121290 is a clinical study titled "SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery". This phase I trial studies the side effects and best dose of SJG-136 in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from d...
What is the current status of trial NCT00121290?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2005-02.
What interventions are being tested in trial NCT00121290?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), SJG-136 (DRUG).
Who is sponsoring clinical trial NCT00121290?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.